期刊文献+

中医外治法干预尼妥珠单抗联合化疗致反应性药疹的临床研究 被引量:3

The research of external treatment of Chinese medicine on the epispasis induced by Nimotuzumab combined with Chemotherapy
下载PDF
导出
摘要 目的:观察梅花针叩刺联合活血解毒中药用于治疗尼妥珠单抗联合化疗过程中反应性药疹,以期为更好的提高晚期肿瘤患者药物依从性及生活质量提供论据支持。方法:90例晚期肿瘤患者均接受尼妥珠单抗联合其他化疗药的治疗,2周后评价按RECIST标准实体瘤情况,并根据是否产生药疹将其随机分为实验组及对照组。实验组行梅花针局部叩刺联合白花蛇舌草、苦参等活血解毒药物进行干预,对照组行生理盐水干预。经过2周与6周的综合治疗再次评估药疹变化情况;药疹标准参考加拿大国立癌症研究所扩大通用性标准(NCIC GTG分级)。结果:56例有药疹发生,且其实体瘤评估控制率与有效率与无药疹发生病例无明显差别;进一步评估56例入组药疹患者不同处理后药疹的变化情况,随机分成2组每组各28人,分中医外治干预组及空白对照组。治疗2周:出疹的患者实验组1级药疹率50‰2级39.3%,3级10.7%,实验组药疹情况控制于1级(◆P<0.05),实验组2级、3级药疹的发病率显著低于对照组(◆P<0.05)。治疗6周:实验组出现1级药疹35.7%,2级50%,3级14.3%;对照组3级42.9%,4级14.3‰实验组药疹控制在1级与2级(◆P<0.05),3级药疹的发病率显著低于对照组(★P<0.05)。结论:本研究表明,药疹与尼妥珠单抗药效无明显对应关系,同时活针药结合法可显著改善由于尼妥珠单抗联合化疗产生的药疹。 Objective: To observe the effect ofpercussopunctator combined with Herbs (promoting blood circulation and detoxication, Huo-Xue-Jie-Du) on epispasis induced by Nimotuzumab combined with Chemotherapy. The aim of this study is to improve the drug dependence and their life quality of advanced cancer patients. Method: We selected 90 patients who received the combined therapy of Nimotuzumab & Chemotherapy. The solid tumor was detected by RECIST standard, and the epispasis patients would be separated into two groups, experimental group vs controls. The experimental group was to intervened with percussopunctator combined with Herbs, such as oldenlandia diffiasa, sophora flavescens air et al. The controls were intervened with physiological saline. 6 weeks later, solid tumor and the epispasis was detected according to NCIC GTG Results: 56 patients suffered epispasis, while the solid statue was no different. We fttrther treated the epispasis by Chinese medicine. Both the experimental group and the control group have 28 patients. 2 weeks: The epispasis of experimental group was 50%, second epispasis 39.3%, third 'degree 10.7%; first degree epispasi was more in experimental group (◆P〈 0.05) ; compared with controls, second and third degree epispasis was lower (◆P〈0.05). 6 weeks: The first degree epispasis of experimental group was 35.7%, second epispasis 42.9%, third degree 14.3%; first and second degree epispasi was more in experimental group (◆P〈0.05). Compared with controls, third degree epispasi was lower in experimental group (★P〈0..05); and there was no fourth degree.. Concliasion: There is no direct connection between epispasis induced by Nimotuzumab; the treatment of percussopnnctator combined with Herbs got its effect on epispasis induced by Nimotuzumab combined with Chemotherapy.
作者 李静 钱彦方
出处 《中医临床研究》 2015年第3期62-65,共4页 Clinical Journal Of Chinese Medicine
基金 国家自然科学基金-青年科学基金项目(81102678)
关键词 尼妥珠单抗 药疹 梅花针 活血解毒法 Nimotuzumab Epispasis Percussopunctator Promoting blood circulation and detoxication
  • 相关文献

参考文献11

  • 1Rivera F, Vega-Villegas ME, Lopez-Brea MF, etal. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta oncologica (Stockholm, Sweden) 2008,47:9-19. 被引量:1
  • 2Lam C, Bouffet E, Bartels U. Nlmotuzumab in pediatric glioma. Future oncology (London, England) 2009,5:1349-1361. 被引量:1
  • 3Nassar D, Soutou B, Aractingi S. Cutaneous side effects of EGF receptor inhibitors. Bulletin du cancer 2009,96 Suppl:S85-91. 被引量:1
  • 4Moustou AE, Matekovits A, Dessinioti C, etal. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review.Journal of the American Academy of Dermatology 2009,61:486-504. 被引量:1
  • 5Deslandres M, Siband V, Chevreau C, etal.Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors. Annales de dermatologie et de venereologie 2008;Spec No 1:16-24. 被引量:1
  • 6Ramakrishnan M S, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin[C]//MAbs. 2009, 1(1): 41-8. 被引量:1
  • 7Arteaga ME, Ledon N, C.asaco A,etal. Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti- epidermal growth factor receptor monoclonal antibody Nimotuzumab. Cancer biology & therapy 2007,(6): 1390-1395. 被引量:1
  • 8王璐,谢晓冬.人类表皮生长因子受体抑制剂的相关皮肤毒性[J].国际肿瘤学杂志,2012,39(10):784-787. 被引量:4
  • 9宋丹丹,卢任期.表皮生长因子受体抑制剂的皮肤反应及治疗[J].国际皮肤性病学杂志,2010,36(6):322-324. 被引量:5
  • 10张艳峰,皮先明.梅花针加辣椒碱软膏治疗带状疱疹后遗神经痛临床观察[J].中国皮肤性病学杂志,2007,21(2):71-71. 被引量:8

二级参考文献35

  • 1陈锐深.易瑞沙所致皮疹的中医药治疗[J].华夏医药,2007,2(2):99-100. 被引量:2
  • 2黑川一郎 田中玄明 池田忠世.西洛他唑内服疗法对带状疱疹后遗神经痛的疗效.药理与治疗,1991,82(2):231-233. 被引量:2
  • 3Li J, Peccerillo J, Kaley K, et al. Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP, 2009, 10(3) :338-340. 被引量:1
  • 4Giovannini M, Gregorc V, Belli C, et al. Clinical significance of skin toxicity due to EGFR-targeted therapies. J Oneol, 2009, 84_0051:1-8. 被引量:1
  • 5Burtness B, Anadkat M, Basti S, et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw, 2009, Suppl 1 :S5-21 ; quiz S22-24. 被引量:1
  • 6Peuvrel L, Bachmeyer C, Reguiai Z, et al. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Support Care Cancer, 2012, 20(5) :909-921. 被引量:1
  • 7Hassel JC, Kripp M, A1-Batran S, et al, Treatment of epidevnal growth factor receptor antagonist-induced skin rash : results of a survey among German oncologists. Onkologie, 2010, 33 (3) :94-98. 被引量:1
  • 8Saif MW, Kaley K, Lamb L, et al. Management of skin toxicities of anti-EGFR agents in patients with pancreatic cancer and other GI tumors by using electronic communication: effective and convenient. JOP, 2010, 11(2) :176-182. 被引量:1
  • 9Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monochmal antibody that retains anti-EGFR activity while minimizing skin toxici- ty. Expert Opin Biol Ther, 2009, 9(9) :1199-1206. 被引量:1
  • 10Xue M, Chow SO, Dervish S, et al. Activated protein C enhances human keratinocyte barrier integrity via sequential activation of epider- mal growth factor receptor and Tie2. J Biol Chem, 2011, 286 ( 8 ) : 6742-6750. 被引量:1

共引文献40

同被引文献109

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部